Please wait

0001178670Alnylam Pharmaceuticals, Inc.S-8S-8EX-FILING FEESN/A7,000,000Otheriso4217:USDxbrli:pure000117867012026-02-122026-02-1200011786702026-02-122026-02-12

Exhibit 107.1

Table 1. Newly Registered Securities

CALCULATION OF REGISTRATION FEE

Security Type

Security Class Title

Fee Calculation Rule

Amount Registered(1)

Proposed Maximum Offering Price per Share(2)

Maximum Aggregate Offering Price

Fee Rate

Amount of Registration Fee

Equity

Common Stock, $0.01 par value per share

Other(2)

7,000,000 shares(3)

$321.94

$2,253,580,000

$0.0001381

$311,219.40

Total Offering Amounts

$2,253,580,000

$311,219.40

Total Fee Offsets

$0

Net Fee Due

$311,219.40

(1)						Pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of common stock which become issuable under the Registrant’s Second Amended and Restated 2018 Stock Incentive Plan (the “Amended Plan”) by reason of any stock dividend, stock split, recapitalization or any other similar transaction effected without the receipt of consideration which results in an increase in the number outstanding shares of the Registrant’s common stock.
(2)						Estimated in accordance with Rule 457(c) and Rule 457(h) solely for the purpose of calculating the registration fee on the basis of $321.94 per share, which is the average of the high and low prices of the common stock on February 10, 2026, as reported on the Nasdaq Global Select Market.
(3)						Represents 7,000,000 shares of common stock that were added to the shares authorized for issuance under the Amended Plan, pursuant to the approval of the Amended Plan approved by the Registrant’s board of directors (the “Board”) on February 27, 2025 and its stockholders on May 8, 2025.

167427502_2